15.07.2024 08:00:05 - dpa-AFX: GNW-Adhoc: Nyxoah Appoints Scott Holstine as Chief Commercial Officer
Nyxoah Appoints Scott Holstine as Chief Commercial Officer
Mont-Saint-Guibert, Belgium - July 15, 2024, 8:00am CET / 2:00am ET - Nyxoah SA
(Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical
technology company focused on the development and commercialization of
innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the
appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott
will lead the commercial operations of Nyxoah enabling a successful U.S. launch.
Scott brings over 26 years of experience in the medical device industry with a
proven track record in U.S. product launches, building and leading commercial
organizations trademarked by strong operational execution. Scott is a passionate
advocate for people and talent development. Scott graduated with the
Superintendent's Award for Excellence (Star Wreath) from the United States
Military Academy at West Point, NY. After serving as a Captain in the U.S. Army,
Scott received his MBA from the University of Minnesota, Carlson School of
Management - Minneapolis, MN.
"As we expect FDA approval by the end of 2024, the hiring of an experienced
commercial leader is instrumental in further accelerating our U.S. go-to-market
strategy into a concrete launch execution plan. This starts with having a
commercial team fully operational by year-end. Scott is a dynamic and creative
leader with countless accomplishments in building high-performing teams and
developing new markets for innovative technologies," commented Olivier Taelman,
Nyxoah Chief Executive Officer. "This appointment is the kickoff of building a
team of world-class patient- and clinician-focused professionals, supporting
Nyxoah's mission to make sleep simple again for OSA patients."
"This is a promising time for patients with OSA. Nyxoah's strong DREAM study
results and Genio's success in markets outside of the U.S. have demonstrated the
potential of Genio's breakthrough and unique solution. Both patients and
physicians are eagerly awaiting a second player in the HGNS field. I am thrilled
to be part of the team building out a patient-focused commercial operation that
prioritizes the success of our healthcare provider partners in treating OSA,"
added Scott.
About Nyxoah
Nyxoah is a medical technology company focused on the development and
commercialization of innovative solutions to treat Obstructive Sleep Apnea
(OSA). Nyxoah's lead solution is the Genio® system, a patient-centered, leadless
and battery-free hypoglossal neurostimulation therapy for OSA, the world's most
common sleep disordered breathing condition that is associated with increased
mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision
that OSA patients should enjoy restful nights and feel enabled to live their
life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system
received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on
Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the
positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval
for the expansion of its therapeutic indications to Complete Concentric Collapse
(CCC) patients, currently contraindicated in competitors' therapy. Additionally,
the Company announced positive outcomes from the DREAM IDE pivotal study for FDA
and U.S. commercialization approval.
For more information, please see the Company's annual report for the financial
year 2023 and visit http://www.nyxoah.com/.
Caution - CE marked since 2019. Investigational device in the United States.
Limited by U.S. federal law to investigational use in the United States.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-
looking, which reflect the Company's or, as appropriate, the Company directors'
or managements' current expectations regarding the entry into of the loan
facility agreement and the synthetic warrant agreement with the EIB; the use of
proceeds from the loan facility agreement; the Genio® system and ongoing
clinical studies of the Genio® system; the potential advantages of the Genio®
system; Nyxoah's goals with respect to the development, regulatory pathway and
potential use of the Genio® system; the utility of clinical data in potentially
obtaining FDA approval of the Genio® system; reporting data from Nyxoah's DREAM
U.S. pivotal trial; filing for FDA approval; and entrance to the U.S. market. By
their nature, forward-looking statements involve a number of risks,
uncertainties, assumptions and other factors that could cause actual results or
events to differ materially from those expressed or implied by the forward-
looking statements. These risks, uncertainties, assumptions and factors could
adversely affect the outcome and financial effects of the plans and events
described herein. Additionally, these risks and uncertainties include, but are
not limited to, the risks and uncertainties set forth in the "Risk Factors"
section of the Company's Annual Report on Form 20-F for the year ended December
31, 2023, filed with the Securities and Exchange Commission ("SEC") on March
20, 2024, and subsequent reports that the Company files with the SEC. A
multitude of factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or results to
differ significantly from any anticipated development. Forward looking
statements contained in this press release regarding past trends or activities
are not guarantees of future performance and should not be taken as a
representation that such trends or activities will continue in the future. In
addition, even if actual results or developments are consistent with the
forward-looking statements contained in this press release, those results or
developments may not be indicative of results or developments in future periods.
No representations and warranties are made as to the accuracy or fairness of
such forward-looking statements. As a result, the Company expressly disclaims
any obligation or undertaking to release any updates or revisions to any
forward-looking statements in this press release as a result of any change in
expectations or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based, except if specifically
required to do so by law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such person's
officers or employees guarantees that the assumptions underlying such forward-
looking statements are free from errors nor does either accept any
responsibility for the future accuracy of the forward-looking statements
contained in this press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on forward-looking statements,
which speak only as of the date of this press release.
Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com (mailto:IR@nyxoah.com)
For Media
Belgium/France
Backstage Communication - Gunther De Backer
gunther@backstagecom.be (mailto:gunther@backstagecom.be)
International/Germany
MC Services - Anne Hennecke
anne.hennecke@mc-services.eu (mailto:anne.hennecke@mc-services.eu)
Â